Immunotherapy of murine leukemia. V. Protection against Friend leukemia virus-induced immune complex glomerulonephritis by passive serum therapy.
The development of immune complex glomerulonephritis in DBA/2 mice infected with Friend murine leukemia virus (F-MuLV) was compared with that in mice protected against virus-induced disease by administration of chimpanzee anti-F-MuLV antiserum (CaF-MuLV). Morphologic analysis of glomeruli from viremic (infected) normal chimpanzee serum-treated animals revealed significant renal disease within 2 weeks following virus inoculation, with glomerular immune complex deposits and C-type viral particles seen by electron microscopy. Localization of F-MuLV envelope and core antigens (gp71 and p30, respectively) was also detected by immunofluorescence, as was murine IgG and C3. However, age-matched DBA/2 mice treated with CaF-MuLV antiserum alone or following F-MuLV inoculation showed no evidence of systemic disease and neither localization of F-MuLV antigens nor detectable virus particles. These data indicate that in addition to erythroleukemia, F-MuLV infection results in severe immune complex glomerulonephritis and that passive immunotherapy can protect susceptible mice from both aspects of viral pathogenesis.
D000818:Animals; D000914:Antibodies, Viral / Q000008:administration & dosage*; D005260:Female; D005622:Friend murine leukemia virus / Q000276:immunology*; D005921:Glomerulonephritis / Q000517:prevention & control*; D007105:Immune Complex Diseases / Q000517:prevention & control*; D007116:Immunization, Passive; D007167:Immunotherapy; D004915:Leukemia, Erythroblastic, Acute / Q000276:immunology; D007942:Leukemia, Experimental / Q000150:complications / Q000276:immunology / Q000628:therapy*; D051379:Mice; D008811:Mice, Inbred DBA
D000914:Antibodies, Viral